To better understand patient-reported quality of life (PRQOL) for patients with head and neck cancer, PRQOL scores were collected in a clinical trial. METHODS: Patients were randomized to arm A (70 Gy of radiation with cisplatin) or arm B (70 Gy of radiation with cisplatin plus erlotinib at 150 mg daily). PRQOL scores were measured on days -7 (arm B only), 0, 30, and 180 with the University of Washington Quality of Life Questionnaire. Associations with clinical factors and outcomes were explored with linear mixed, logistic, and Cox regression models. RESULTS: One hundred eighty-nine patients (97 in arm A and 92 in arm B) consented to PRQOL collection. Patients were balanced apart from more females in arm A (20 [21%] vs 8 [9%]; P 5.02). There were 17 black patients (18%) in arm A and 12 (13%) in arm B (P 5.39). There was no change in the mean scores in arm B from day -7 to day 0 (P 5.36). Scores were lower in both arms at day 30 (P for both < .0001), with no difference by arm (P 5.10). Scores on day 180 remained lower for arm A (-6.79; 95% confidence interval [CI], -12.6 to -1.0; P 5.02). In arm B, this difference was not significant, and this suggested that the scores had returned to the baseline by day 180 (P 5.73). After adjustments for potential confounders, black race was an independent predictor for inferior scores 95% CI,; P <.0001), complete response rates (odds ratio, 0.34; 95% CI, 0.12-0.91; P 5.03), and overall survival (hazard ratio, 3.71; 95% CI, 1.63-8.47; P <.01). CONCLUSIONS: PRQOL scores predictably worsened during and improved after chemoradiation. Black patients had inferior PRQOL and overall survival. Cancer 2018;124:2841-9.
INTRODUCTION
Squamous cell carcinomas of the head and neck have been traditionally linked to tobacco and alcohol exposure. There is an overrepresentation of patients with comorbidities, ethnic minorities, and the socioeconomically marginalized in the head and neck cancer population.
1,2 Viral etiologies have been implicated in certain subsets of patients, such as patients with nasopharynx carcinoma (Epstein-Barr virus) 3 and oropharynx cancer (human papillomavirus). 4 The majority of newly diagnosed patients present with locally advanced disease and are potential candidates for curative-intent treatment. Curative-intent therapeutic strategies often involve a multimodality approach consisting of a combination of surgical resection, radiation therapy, and/or chemotherapy. [5] [6] [7] [8] Advances and refinements in curative-intent therapy have successfully improved locoregional and distant control rates in these patients, but they entail significant acute toxicities and nontrivial rates of long-term loss of function and disability. 9, 10 The incremental improvements in survival among patients undergoing curative-intent therapy have naturally underscored the significance of measuring patient-reported quality of life (PRQOL) outcomes in this population, in which the anatomic location of the tumor and treatment toxicities often result in adverse functional sequelae. There are several prospectively validated PRQOL instruments that measure patient symptoms, and they encompass several domains, which include but are not limited to emotional, physical, functional, social, financial, and spiritual realms. Tools such as the MD Anderson Dysphagia Inventory, 11 Functional Assessment of Cancer Therapy-Head and Neck, 12 and Functional Oral Intake Scale 13 measure patient satisfaction in domains relevant to this population, such as the ability to speak, swallow, taste, and eat food. Our group at the University of Washington Medical Center has developed and validated a PRQOL tool, the University of Washington Quality of Life Questionnaire, version 4.0 (UWQOL v4). [14] [15] [16] [17] This tool asks 12 domain questions based on patient symptoms and treatment-related side effects for the 7 days before the administration of the questionnaire. These domains include pain, appearance, activity, recreation, swallowing, chewing, speech, shoulder function, taste, saliva, mood, and anxiety. In addition to the 12 domain questions, the questionnaire also asks patients to disclose the top 3 domains that have been of concern for them over the past 7 days as well as general questions regarding their overall quality of life. Each domain is scored from 0 to 100, with 0 being the worst possible response.
Our institution led an investigator-initiated, industry-sponsored, nonblinded, randomized phase 2 study that was opened in several institutions across the United States and compared 2 curative-intent treatment regimens for squamous cell carcinomas of the head and neck. 18 In this article, we discuss the PRQOL outcome measurements obtained from patients enrolled in this study and exploratory analyses looking at associations between PRQOL scores and outcomes.
MATERIALS AND METHODS

Trial Design
Patients with biopsy-confirmed squamous cell carcinoma of the nasopharynx, larynx, oropharynx, oral cavity, or hypopharynx at stage III to IVB (American Joint Committee on Cancer system, version 7) were enrolled in this clinical trial and randomized to 1 of 2 treatment arms (see Fig. 1 ): arm A, in which cisplatin at 100 mg/m 2 was given on days 1, 22, and 43 of radiation therapy, and arm B, in which patients received the same chemoradiation regimen used in arm A along with erlotinib at 150 mg daily, which was started 7 days before radiation initiation and was continued until radiation completion. This clinical trial was reviewed and approved by the Fred Hutchinson Cancer Research Center Institutional Review Board.
Patients consented to central tumor p16 testing of available formalin-fixed, paraffin-embedded tumor tissue, which was performed at the University of Washington with the CINtec assay (Ventana Medical Systems, Tucson, Arizona). p16 positivity was defined as strong, diffuse nuclear and cytoplasmic staining in 70% of tumor cells.
The primary endpoint of this trial was the complete response rates in both treatment arms, and the oncologic outcomes of this trial have been previously published. 18 Observations of subjective symptom improvement among patients treated with erlotinib and platinum-based chemoradiation in an earlier prospective study 19 led to interest in examining PRQOL in this randomized phase 2 trial. PRQOL collection using our institutional tool (UWQOL v4) was included as a secondary and exploratory study endpoint.
All patients were offered participation in the PRQOL component of the trial, which was performed with the UWQOL v4. For patients in both arms, PRQOL were measured on days 0, 30, and 180. An additional PRQOL time-point collection was performed on day -7 among patients randomized to arm B. For each patient, at every PRQOL measurement time point, a mean PRQOL score was calculated by the averaging of the scores obtained from each of the 12 domains of the UWQOL v4.
Statistical Analysis
Patient demographic information, tumor characteristics, treatment-group data, and response data were summarized as proportions for categorical variables and as means and ranges for continuous variables. Demographic traits and tumor characteristics were compared between arm A and arm B with the Fisher exact test for categorical variables and with the Student 2-sample t test for continuous variables. Survival distributions were estimated with the Kaplan-Meier method. Overall survival was defined as the time from the date of trial registration to the date of death from any cause. Patients last known to be alive were censored at the date of last contact. Multivariate Cox regression analysis was used to explore the associations between survival, PRQOL scores, and treatment arm. Linear mixed models were used to examine the relation between treatment arm and PRQOL scores over time. Logistic regression models were used to analyze the relation between response and treatment arm. All models controlled for demographic variables and tumor characteristics. Objective responses at the end of treatment were defined with the Response Evaluation Criteria in Solid Tumors (version 1.1). 20 All statistical analyses were performed with SAS 9.4. A 2-sided significance level of .05 was used for all analyses.
RESULTS
PRQOL Data Acquisition
Two hundred four patients were enrolled in this clinical trial between December 2006 and October 2011. Ten institutions participated in this study, and 189 patients (93%) consented to PRQOL collection. Of the 105 patients in arm A, 97 consented to PRQOL collection (Fig. 2) . PRQOL data for days 0, 30, and 180 were available for 54, 65, and 45 of the consenting patients, respectively. Among the 99 patients randomized to arm B, 92 consented to PRQOL collection, and PRQOL scores were available for 78, 56, 67, and 40 at days -7, 0, 30, and 180, respectively, among the consenting patients. Table 1 summarizes the PRQOL collection rates and mean scores obtained at each time point. 
Patient Demographics and Tumor Characteristics
The patients were well balanced in terms of age, race, and Eastern Cooperative Oncology Group (ECOG) performance status at enrollment (Table 2) as well as T and N stages and primary site locations. There were significantly more females enrolled in arm A versus arm B (20 [21%] vs 8 [9%]; P 5 .02). The majority of the patients in the study were white (arm A, 80%; arm B, 82%); the second most frequent race was black. Black patients were equally distributed, with 17 (18%) and 12 (13%) enrolled in arms A and B, respectively. There were 72 current and former smokers (74%) in arm A and 73 (79%) in arm B. Of the 145 total current and former smokers enrolled in the study, 27 (19%) were black, and 118 (81%) were nonblack. The most common primary site was the oropharynx, with 59 patients (61%) in arm A and 62 patients (67%) in arm B.
Central testing for p16 was performed in 90 of the 204 patients enrolled (44%). In arm A, the p16 status was positive in 27 patients (28%), negative in 16 patients (16%), and untested/unknown in 54 patients (56%). In arm B, the p16 status was positive in 26 patients (28%), negative in 18 patients (20%), and untested/unknown in 48 patients (52%) There was a lower rate of p16 positivity among black patients versus nonblack patients (4 of 29 black patients [14%] vs 49 of 111 nonblack patients [31%]; P 5 .07). The distributions of patient demographics and tumor characteristics are detailed in Tables 2 and 3 , respectively. Table 1 presents a summary of the completion rates and mean scores for both treatment arms by each time point. Original Article
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Cancer Figure 3A graphically displays the mean PRQOL scores at each time point for each arm of the study. The results in the table and figure are not adjusted for dropout patterns or missing data after the baseline. Mean scores were not significantly different between the arms with the exception of day 180; patients in arm B had higher mean scores than those in arm A (P 5 .02). Table 4 presents the results of an unadjusted timevarying analysis. The mean PRQOL scores among patients randomized to arm B were not significantly different between day -7 and day 0 (mean change in average score from day 0, -2.26; 95% confidence interval [CI], -7.2 to 2.6; P 5 .36). There was a significant decline in the mean PRQOL scores from the baseline (day 0) to day 30 in both treatment arms (arm A, -13.44; 95% CI, -18.7 to -8.2; P < .0001; arm B, -12.86; 95% CI, -17.9 to -7.8; P < .0001). The PRQOL score increased from day 30 to day 180 in both groups. The difference in mean scores between the baseline and day 180 in arm B was not significant (-1.02; 95% CI, -6.8 to 4.8; P 5 .73). However, day 180 scores remained statistically lower than the baseline scores for patients randomized to arm A (-6.79; 95% CI, -12.6 to -1.03; P 5 .02). Table 5 presents the results of a time-varying analysis that has been adjusted for patient factors, including age, sex, race, smoking, and performance status. Black race, current smoking (vs former and never smoking), and a poorer performance status were significantly associated with lower mean PRQOL scores independent of the treatment arm and time point (P for black race and an ECOG performance status of 1 < .0001; P for current smoking 5 .003). Mean PRQOL scores among black patients were 11.39 points lower than those among nonblack patients (95% CI, -16.84 to -5.94). The mean scores were 9.00 points lower for current smokers versus former/never smokers (95% CI, -14.1 to -3.68) and for patients with an ECOG performance status of 1 versus 0 (95% CI, -13.07 to -4.94). In these adjusted analyses, with respect to the baseline (day 0), mean scores were significantly lower at day 30 (P < .0001) and day 180 (P 5 .03). The mean scores were 13.32 points lower than the baseline scores at day 30 (95% CI, -18.73 to -7.91) and 6.88 points lower than the Abbreviations: CI, confidence interval; N/A, not applicable; PRQOL, patient-reported quality of life. This unadjusted, time-varying analysis shows that the mean PRQOL scores among patients randomized to arm B were not significantly different between days -7 and 0, although there was a significant decline from the baseline to day 30 in both arms (P <.0001). PRQOL scores increased in both groups between days 30 and 180, although they remained lower than the baseline in arm A only. The bolded P values are significant.
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Cancer July 1, 2018 baseline scores at day 180 (95% CI, -12.89 to -0.87). There was no statistically significant difference between the treatment arms overall (P 5 .43). A positive p16 status was not a predictor for superior PRQOL scores in comparison with a negative or unknown p16 status (-1.82; 95% CI, -6.01 to 2.37; P 5 .39). Table 6 presents the results of the analysis of 2 oncologic outcomes of interest (complete response to treatment and overall survival) and the association with demographic traits and tumor characteristics. Black race was significantly associated with a lower complete response rate (odds ratio, 0.34; 95% CI, 0.12-0.91; P 5 .03) and an increased risk of death (hazard ratio [HR], 3.71; 95% CI, 1.63-8.47; P < .01). The ECOG performance status, p16 status, age, and treatment arm did not have a statistical impact on either oncologic outcome among patients enrolled in this study (see Table 6 ). Current and former smoking was not associated with decreased complete response rates but was an independent predictor of inferior overall survival (HR for current smokers, 9.03; 95% CI, 1.13-72.07; P 5 .04; HR for former smokers, 8.18; 95% CI, 1.08-61.83; P 5 .04). The Kaplan-Meier curves for overall survival according to race are shown in Figure 3B .
DISCUSSION
The refinement of oncologic treatments and supportive care and the validation of PRQOL measurement tools have generated a growing body of PRQOL literature across multiple malignancies. [21] [22] [23] There are data associating superior PRQOL scores with improved survival and oncologic outcomes of therapy for patients, [24] [25] [26] including patients with head and neck cancer. 27, 28 As a result, patient-reported outcomes are accepted standard endpoints for measuring the efficacy of contemporary cancer therapies, and they intuitively give merit to identifying factors that predict superior scores. Racial disparity is one factor that has been repeatedly shown to negatively affect patient-reported outcomes. Sanda et al 29 prospectively measured PRQOL outcomes in 1201 patients with prostate cancer and found inferior PRQOL scores in black patients. A similar observation was made in 650 patients with lung cancer for whom PRQOL was measured after surgical resection. 30 Racial disparities in outcomes and therapy are well established in head and neck cancer, a disease traditionally linked to a lifestyle involving heavy tobacco and alcohol exposure and, subsequently, having a predominance of patients belonging to lower socioeconomic strata, or ethnic minorities. More advanced stages at diagnosis, worse overall survival, and disease-free survival in black patients in comparison with white counterparts have been reproducibly documented in this disease. [31] [32] [33] [34] Hayes et al 35 reported observations gleaned from a large longitudinal registry data of patients with head and neck cancer (the Longitudinal Oncology Registry of Head and Neck Carcinoma), in which black race was associated with lower income, lower educational attainment, higher rates of tobacco use, and poorer performance status. The etiology of these differences is poorly understood but has been attributed to differences in both biologic and environmental factors. 31 Recently published data suggest that the emergence of the human papillomavirus-related oropharynx subset, a unique entity that has a higher incidence in younger, white males and carries a superior prognosis, has widened the oncologic outcome gap between white and black patients. [36] [37] [38] Our results represent the largest prospective evaluation of PRQOL using the UWQOL v4 in patients treated with definitive platinum-based chemoradiation, and this is, to our knowledge, the first report of racial disparities in PRQOL using this tool. Our data support and are consistent with published literature on the relationship of race with outcomes among patients prospectively evaluated for PRQOL in clinical trials. Unlike population-and registry-based data sets, patients enrolled in curativeintent clinical trials are often regarded as poorly representative of the general head and neck cancer population in that trial eligibility criteria often preselect for a fitter patient population with improved access to health care. We observed disparities despite trial preselection and the uniform protocol-directed curative-intent therapy, which was performed in high-volume academic centers in the United States. Our results likely speak to the complex interaction of various factors that are difficult to measure in this population, such as psychosocial distress, a lack of emotional support, and socioeconomic disadvantages, among others, that may predominate among black patients.
Our data have several weaknesses, the first and most obvious one being the incomplete PRQOL data collected in both arms and at each study time point. Second, a more in-depth analysis of PRQOL by domain, which we were unable to perform, might have revealed specific aspects of PRQOL that are inferior in the black population, and this could potentially lead to focused efforts at mitigation. Third, our trial was not designed to measure PRQOL past day 180 after radiation therapy; therefore, we were unable to collect data on long-term well-being and factors that influence this. Fourth, our inability to observe an association between p16, an established prognostic marker for oropharynx cancer, and outcomes is likely related to the low rate of p16 testing performed during the study. It is highly probable that prognostically superior p16-positive patients were inadvertently included in the p16-negative/unknown group. Fifth, data were not obtained regarding socioeconomic contributors. Collection of these data would have allowed us some insight into the impact of these factors on PRQOL and outcomes as well as their relation with race and tobacco use. Sixth, the UWQOL v4 tool, though validated, has been most extensively studied in patients with head and neck cancer who have undergone surgical resection. 39 The inclusion of a more extensively studied PRQOL tool in patients treated with chemoradiation (eg, Functional Assessment of Cancer Therapy-Head and Neck) would perhaps have given us some insight into how the UWQOL v4 compares with these more widely used PRQOL measurements. Finally, it must be emphasized that in this randomized phase 2 study, PRQOL collection was an exploratory endpoint meant to generate preliminary data with our institutional PRQOL tool. The trial design did not include prespecified power calculations or sample size determinations to detect differences between PRQOL in the 2 study arms or to detect differences in PRQOL according to race.
Patients in arm B experienced a return to PRQOL baseline scores at day 180, unlike those in arm A, despite no observed difference in complete response rates in the 2 arms. In addition, although a statistically significant increase in dermatologic toxicity was reported in arm B, 18 no differences in the mean scores were noted between the 2 arms at all collection time points. These observations are inconsistent with the published PRQOL results from Radiation Therapy Oncology Group (RTOG) 0522, 40 which explored the addition of another epidermal growth factor receptor inhibitor, cetuximab, to cisplatin-based radiation and compared this to cisplatin and radiation. The RTOG 0522 investigators observed worse PRQOL at 3 months and 1 year after treatment in patients receiving cetuximab. A potential reason for these observations is a limitation within the UWQOL v4 instrument in reflecting dermatologic toxicity. Unlike our study, RTOG 0522 obtained comprehensive, multitool PRQOL data from a much larger population, with more robust rates of PRQOL completion, and at extended time points of up to 5 years after treatment completion. Our observation of worse survival among patients with continued and prior tobacco exposure is consistent with previously published reports of patients undergoing chemoradiation for upper aerodigestive malignancies. [41] [42] [43] Reduced therapeutic efficacy among current and former smokers may be related to comorbidity, tumor hypoxia, tumor mutational burden, and nicotine/drug interactions. Our findings also contribute to the growing body of literature linking smoking to inferior quality of life in patients with upper aerodigestive malignancies. [44] [45] [46] [47] These findings place an emphasis on the critical role of tobacco counseling in the comprehensive, multidisciplinary management of head and neck carcinomas.
It is clear that in this current environment of health care reform, cancer prevention and the elimination of racial disparities in cancer treatment outcomes should remain urgent priorities. Public policies, such as the Affordable Care Act, geared toward eradicating barriers to medical care and improving access to preventive care have resulted in a reduction in the number of uninsured individuals in the United States and in mandated insurance coverage of evidence-based smoking-cessation interventions. 48 Overcoming challenges and developing specific measures to improve outcomes among vulnerable populations cannot be accomplished if the phenomenon of disparity is not studied more closely. As evidenced by our experience and supported by literature in other malignancies, 49, 50 ethnic minorities are sorely underrepresented in clinical trials. Without addressing impediments to their inclusion in prospective studies, it will be difficult to obtain valuable data needed to identify factors that influence outcomes in these groups. Our data underscore the need for more in-depth analyses of these quality-of-life and outcome disparities in both the clinical trial and offprotocol settings to ultimately transform the ideal of universal health care into reality. As oncology clinics (including ours) begin to include patient-reported outcome measures in the routine oncology clinic workflow, 51 we hope that further insights will soon become available regarding the associations of symptoms, health-related quality of life, and oncologic outcomes.
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